Phosphodiesterase inhibitors: Potential role in the respiratory distress of neonates
- PMID: 29905405
- DOI: 10.1002/ppul.24082
Phosphodiesterase inhibitors: Potential role in the respiratory distress of neonates
Abstract
Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the hydrolysis of phosphodiester bonds of 3',5' cyclic adenosine and guanosine monophosphate (cAMP and cGMP). PDEs control hydrolysis of cyclic nucleotides in many cells and tissues. Inhibition of PDEs by selective or nonselective PDE inhibitors represents an effective targeted strategy for the treatment of various diseases including respiratory disorders. Recent data have demonstrated that PDE inhibitors can also be of benefit in respiratory distress in neonates. This article outlines the pharmacological properties of nonselective and selective PDE inhibitors and provides up-to-date information regarding their use in experimental models of neonatal respiratory distress as well as in clinical studies.
Keywords: neonate; phosphodiesterase inhibitors; respiratory distress.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension.Handb Exp Pharmacol. 2011;(204):251-77. doi: 10.1007/978-3-642-17969-3_11. Handb Exp Pharmacol. 2011. PMID: 21695644 Free PMC article. Review.
-
Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.Mol Pharmacol. 1991 Mar;39(3):376-84. Mol Pharmacol. 1991. PMID: 1848659
-
Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?Int J Mol Sci. 2021 Feb 16;22(4):1929. doi: 10.3390/ijms22041929. Int J Mol Sci. 2021. PMID: 33669167 Free PMC article. Review.
-
Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.Eur J Pharmacol. 2015 Jan 5;746:14-21. doi: 10.1016/j.ejphar.2014.10.018. Epub 2014 Nov 11. Eur J Pharmacol. 2015. PMID: 25446933
-
Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs).Curr Top Med Chem. 2022;22(3):209-228. doi: 10.2174/1568026621666210909164118. Curr Top Med Chem. 2022. PMID: 34503407 Review.
Cited by
-
Acute Lung Functional and Airway Remodeling Effects of an Inhaled Highly Selective Phosphodiesterase 4 Inhibitor in Ventilated Preterm Lambs Exposed to Chorioamnionitis.Pharmaceuticals (Basel). 2022 Dec 26;16(1):29. doi: 10.3390/ph16010029. Pharmaceuticals (Basel). 2022. PMID: 36678525 Free PMC article.
-
Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules.Front Pharmacol. 2022 Nov 24;13:1057083. doi: 10.3389/fphar.2022.1057083. eCollection 2022. Front Pharmacol. 2022. PMID: 36506513 Free PMC article. Review.
-
Advances in the Study of Inhaled Formulations for the Treatment of Pulmonary Arterial Hypertension.Appl Bionics Biomech. 2022 Jun 2;2022:6495645. doi: 10.1155/2022/6495645. eCollection 2022. Appl Bionics Biomech. 2022. Retraction in: Appl Bionics Biomech. 2023 Nov 29;2023:9868671. doi: 10.1155/2023/9868671. PMID: 35694279 Free PMC article. Retracted. Review.
-
Phosphodiesterases and cAMP Pathway in Pituitary Diseases.Front Endocrinol (Lausanne). 2019 Mar 19;10:141. doi: 10.3389/fendo.2019.00141. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 30941100 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources